Targeting CLEC9A delivers antigen to human CD141(+) DC for CD4(+) and CD8(+)T cell recognition

DC-based vaccines that initiate T cell responses are well tolerated and have demonstrated efficacy for tumor immunotherapy, with the potential to be combined with other therapies. Targeting vaccine antigens (Ag) directly to the DCs in vivo is more effective than cell-based therapies in mouse models...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JCI Insight
Hlavní autoři: Tullett, Kirsteen M., Leal Rojas, Ingrid M., Minoda, Yoshihito, Tan, Peck S., Zhang, Jian-Guo, Smith, Corey, Khanna, Rajiv, Shortman, Ken, Caminschi, Irina, Lahoud, Mireille H., Radford, Kristen J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2016
Témata:
Technical Advance
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5033826/
https://ncbi.nlm.nih.gov/pubmed/27699265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.87102
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky